BLOOMSBURY GENETIC THERAPIES LIMITED

Accounts Submitted 13 Nov 2025

Confirmation Statement Submitted 6 Nov 2025

Net assets £1.30M £2.67M 2023 year on year

Total assets £2.94M £1.35M 2023 year on year

Total Liabilities £1.65M £1.33M 2023 year on year

Charges 3

2 outstanding 1 satisfied

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

Building 1000 Cambridge Research Park Beach Drive Waterbeach Cambridgeshire CB25 9PD England

Office (London)

97 Tottenham Ct Rd, Greater, London W1T 4TP

info@bloomsburygtx.com

Website

bloomsburygtx.com

Credit Report

Discover BLOOMSBURY GENETIC THERAPIES LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2023

Type Total Exemption Full

Next accounts 31 December 2024

Due by 30 September 2025 9 months

Net Assets, Total Assets & Total Liabilities (2022–2023)

Cash in Bank

£2.43M

Decreased by £1.65M (-40%)

Net Assets

£1.30M

Decreased by £2.67M (-67%)

Total Liabilities

£1.65M

Increased by £1.33M (+417%)

Turnover

N/A

Employees

Increased by 2 (+50%)

Debt Ratio

56%

Increased by 49 (+700%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2023 Dec Year End	2022 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share allotments and capital structure

8 Allotments 10,934,739 Shares £5.00m Total

Date From	Share Class	Shares Allotted	Amount Raised	Price/Share
18 Jun 2024	ORDINARY	20,929	£0.209	£0
8 Mar 2024	ORDINARY	34,947	£0.349	£0
21 Aug 2023	ORDINARY	743,750	£7.438	£0
30 Apr 2023	ORDINARY	1,011,112	£10.111	£0
7 Dec 2022	SEED PREFERENCE	2,800,000	£2.80m	£1

Officers

2 active 7 resigned

Show resigned officers

						Status
John Edward Ilett	Secretary	Unknown	Unknown	—	3 Oct 2022	Active
Leigh Pauline Brody	Director	American	England	42	6 Apr 2022	Active

Shareholders

Shareholders (12)


Utf General Partner 2 Llp	45.7%	5,000,001	Seed Preference	24 Sept 2024
Ucl Business Ltd	27.4%	3,001,491	Ordinary	24 Sept 2024
Simon Waddington	4.6%	498,917	Ordinary	24 Sept 2024

Persons with Significant Control

Persons with Significant Control (2)

2 Active 1 Ceased

Utf General Partner 2 Llp

United Kingdom

Active

Notified 6 Apr 2022

Nature of Control

Ownership Of Shares 25 To 50 Percent
Voting Rights 25 To 50 Percent
Right To Appoint And Remove Directors

Ucl Business Ltd

United Kingdom

Active

Notified 9 Aug 2022

Nature of Control

Ownership Of Shares 25 To 50 Percent
Voting Rights 25 To 50 Percent

Ahad Abdul Rahim

Ceased 6 Apr 2022

Ceased

See All Controllers

Group Structure

UCL BUSINESS LTD united kingdom

UTF GENERAL PARTNER 2 LLP united kingdom voting rights 25 to 50 percent limited liability partnership

UTF ALBION MEMBER 2 LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent

UTF ALBION MEMBER LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent

ALBION CAPITAL GROUP LLP united kingdom

BLOOMSBURY GENETIC THERAPIES LIMITED Current Company

Charges

2 outstanding 1 satisfied

Documents

Company Filings

Date	Category	Description	Document
13 Nov 2025	Accounts	Annual accounts made up to 2024-12-31	View(10 pages)
6 Nov 2025	Officers	Termination of John Edward Ilett as director on 2025-03-05	View(1 page)
6 Nov 2025	Confirmation Statement	Confirmation statement made on 2025-08-30 with updates	View(5 pages)
8 Jul 2025	Resolution	Resolutions	View(8 pages)
8 Jul 2025	Incorporation	Memorandum Articles	View(34 pages)